Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) and Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Volatility and Risk
Cullinan Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Cullinan Therapeutics and Arcadia Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cullinan Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Arcadia Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Cullinan Therapeutics and Arcadia Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cullinan Therapeutics | N/A | -36.56% | -34.82% |
| Arcadia Biosciences | -139.36% | -34.75% | -20.91% |
Institutional and Insider Ownership
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are owned by institutional investors. 7.2% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 1.8% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Cullinan Therapeutics and Arcadia Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cullinan Therapeutics | N/A | N/A | -$167.38 million | ($3.23) | -2.43 |
| Arcadia Biosciences | $5.41 million | 1.39 | -$7.04 million | ($4.28) | -1.28 |
Arcadia Biosciences has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Cullinan Therapeutics beats Arcadia Biosciences on 7 of the 13 factors compared between the two stocks.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Arcadia Biosciences
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
